Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
about
A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.The use of model-based tumor-size metrics to predict survival.
P2860
Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
@en
Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
@nl
type
label
Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
@en
Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
@nl
prefLabel
Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
@en
Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
@nl
P2860
P1433
P1476
Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.
@en
P2093
Ben Suttle
Peter L Bonate
P2860
P2888
P304
P356
10.1208/S12248-013-9487-1
P407
P577
2013-04-20T00:00:00Z
P5875
P6179
1041173246